Submit your email to push it up the queue
American Regent, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 1988, the company has established itself as a leader in the development and manufacturing of injectable pharmaceuticals, particularly in the areas of anaesthesia and critical care. With a diverse portfolio that includes essential products such as injectable solutions and specialty pharmaceuticals, American Regent is recognised for its commitment to quality and innovation. The company has achieved significant milestones, including the expansion of its manufacturing capabilities and a robust pipeline of new products. Renowned for its reliability and dedication to patient safety, American Regent continues to strengthen its market position, making notable contributions to healthcare providers and patients alike.
How does American Regent, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
American Regent, Inc.'s score of 55 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
American Regent, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of reported figures. The company is a current subsidiary of Daiichi Sankyo Company, Limited, and thus may inherit emissions data and climate commitments from its parent organisation. While American Regent, Inc. has not set its own reduction targets or initiatives, it is aligned with the sustainability efforts of Daiichi Sankyo Company, Limited. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and RE100, which aim to promote significant reductions in greenhouse gas emissions across the corporate family. As a subsidiary, American Regent, Inc. is expected to adhere to the climate commitments and performance standards set by Daiichi Sankyo, which may include ambitious targets for reducing Scope 1, 2, and 3 emissions. However, specific details regarding these targets or achievements have not been disclosed at this time. In summary, while American Regent, Inc. does not currently report its own emissions data or reduction targets, it is part of a larger corporate structure that is committed to addressing climate change through established initiatives and frameworks.
Access structured emissions data, company-specific emission factors, and source documents
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 182,519,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 290,715,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 5,704,000 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
American Regent, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.